Study Title: Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib For High-Risk Renal Cell Carcinoma (STRIKE)
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Ho, Thai, at hothai@musc.edu.Study Coordinator, Tucker, Renee, at tuckerr@musc.edu.Trial opened at the following institutions: Medical University of South Carolina, Tidelands Health